Toby Freyman, Ph.D., joined BeiGene in 2021 as Vice President, Business Development bringing 20 years of experience in healthcare strategy, R&D, and business development.  Dr. Freyman was most recently Head of Rare Disease and GI Business Development at Takeda’s Center for External Innovation where he led a team focused on building Takeda’s pipeline and Takeda’s Global Gene Therapy platform.  Prior to Takeda, he was in Corporate Development at Shire plc (acquired by Takeda) leading transactions, including in-licensing, strategic collaborations, out-licensing, investments, and spin-outs. Dr. Freyman holds a B.S. from Syracuse University and a Ph.D. in Materials Engineering from the Massachusetts Institute of Technology, where he received an NIH Graduate Fellowship through a joint program with Harvard and MIT.